NCT07198191 - SGLT2 Inhibitor Use After Acute Myocardial Infarction in Patients With Type 2 Diabetes: A Nationwide Cohort Study | Biotech Hunter

Enrollment

200,000

Participants

Timeline

Start Date

September 1, 2014

Primary Completion Date

June 30, 2022

Study Completion Date

August 30, 2026

Conditions

Acute Myocardial Infarction (AMI)Type 2 Diabetes Mellitus (T2DM)

Interventions

DRUG

SGLT2 inhibitors (e.g., dapagliflozin, empagliflozin)

Exposure to SGLT2 inhibitors following AMI in patients with T2DM

DRUG

DPP4 inhibitors

Exposure to DPP4 inhibitors following AMI in patients with T2DM

Trial Locations (1)

Yongin Severance Hospital, Yonsei University Health System, Yongin